Mednet Logo
CommunityMedical Oncology

How would you approach a patient who has developed neutropenia with the combination of trastuzumab/pertuzumab in the adjuvant setting?

Would you consider the discontinuation of either anti-HER2 agent or both?
1 Answer
Mednet Member
Mednet Member
Medical Oncology · Overlook Medical Center
Answered on

I have noted an increase in cytopenias IF the combo is given as Phesgo as compared to IV. I have one patient who had sign cytopenia on Phesgo and did quite well on IV.

Join for free or sign in to see the full answer